RxDoctor Payments DataLook up a doctor →

Kevin Myrie, MD

Nephrology · Merrillville, INNPI 1316193162

Payments from drug & device makers

$51,340in general payments, 2019–2025

Across 479 payments — averaging $107.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$37K
  • AstraZeneca$2K
  • Travere Therapeutics, Inc.$1K
  • Bayer$1K
  • Fresenius USA Marketing, Inc.$1K
  • OPKO Pharmaceuticals, LLC$989
  • plus $7K from 30 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK11$37,062
AstraZeneca(2 entities)68$2,451
Travere Therapeutics, Inc.27$1,340
Bayer31$1,124
Fresenius USA Marketing, Inc.52$1,097
OPKO Pharmaceuticals, LLC58$989
Vifor Pharma, Inc.39$881
Mallinckrodt Hospital Products Inc.20$787
Ardelyx, Inc.17$651
Otsuka America Pharmaceutical, Inc.15$611
Calliditas Therapeutics US Inc.17$601
Mallinckrodt Enterprises LLC5$526
Amgen(2 entities)31$491
ANI Pharmaceuticals, Inc.12$478
Novo Nordisk7$249
Novartis11$225
Regeneron Healthcare Solutions, Inc.2$219
Aurinia Pharma U.S., Inc.6$213
Boehringer Ingelheim5$207
Lilly USA, LLC10$196
Bard Peripheral Vascular, Inc.2$138
Otsuka Pharmaceutical Development & Commercialization, Inc.3$126
Daiichi Sankyo Inc.6$107
Azurity Pharmaceuticals, Inc.2$103
Genentech USA, Inc.4$75
Takeda Pharmaceuticals U.S.A., Inc.3$66
Ultragenyx Pharmaceutical Inc.3$61
Scpharmaceuticals Inc.2$58
Akebia Therapeutics Inc2$43
Kyowa Kirin, Inc.2$40
Apellis Pharmaceuticals, Inc.1$25
Pharmacosmos Therapeutics Inc.1$25
Chiesi USA, Inc.1$19
Karyopharm Therapeutics Inc.1$18
Shire North American Group Inc1$17
Johnson & Johnson1$16

How this compares

$51,340 in reported general payments places this provider in the 85th percentile of 238 nephrology providers in Indiana.

See all nephrology providers in Indiana →

Medicare billing

Part B allowed, 2024
$207,543
Medicare patients
463
Services billed
1,912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in Merrillville

See the full list for Indiana →

Where these figures come from

Is this you, or does something look wrong? →